Multiple Factors in Recurrent Symptomatic Hypocalcemia Following Denosumab in a Patient Receiving Home Parenteral Nutrition

Abstract

Keywords

parenteral nutrition nutrition minerals/trace elements osteoporosis denosumab

Get full access to this article

View all access options for this article.

References

Cummings

Martin

McClung

. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-765.

Okada

Kawazoe

Teraoka

. Identification of the risk factors associated with hypocalcemia induced by denosumab. Biol Pharm Bull. 2013;36:1622-1626.

McCormick

Davis

Burns

. Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis. 2012;60:626-628.

Ungprasert

Cheungpasitporn

Srivali

Kittanamongkolchai

Bischof

. Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency. Am J Emerg Med. 2013;31:756.e751-752.

Shafqat

Alquadan

Olszewski

. Severe hypocalcemia after denosumab in a patient with acquired Fanconi syndrome. Osteoporos Int. 2014;25:1187-1190.

McLachlan

Marx

Bridgman

. Severe symptomatic hypocalcaemia following a single dose of denosumab. Med J Aust. 2013;199:242-243.

Block

Bone

Fang

Lee

Padhi

. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27:1471-1479.

Jamal

Ljunggren

Stehman-Breen

. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26:1829-1835.

Chen

Hsu

. An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab. 2014;99:2426-2432.

10.

Farinola

Kanjanapan

. Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure. Int Med J. 2013;43:1243-1246.